Regeneron: Buy Rating Reaffirmed Amid Growth Prospects and Attractive Valuation

Leerink Partners analyst David Risinger reiterated a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $645.00.

David Risinger has given his Buy rating due to a combination of factors that suggest Regeneron’s stock has the potential to outperform. Despite the setback with itepekimab, which led to a reduction in the price target, the overall impact on the income statement is minimal. This is because the drug was only expected to generate significant sales by 2032 and was partnered with another company, which mitigates the financial impact.
Risinger anticipates that Regeneron will return to growth in 2026, with an acceleration in 2027. This is expected after a decline in Eylea sales in 2025, followed by stabilization. Furthermore, the company’s pipeline is poised for positive developments, with potential approvals for oncology drugs and high-dose Eylea, which could enhance Regeneron’s market position. Additionally, the stock is trading at historically low multiples, presenting an attractive valuation opportunity for investors.

In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $958.00 price target.